EUCTR2011-001015-32-FI进行中（未招募）1 期
A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumabin combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer. - The BOOST (Bevacizumab Ovarian Optimal Standard Treatment) Trial - boost
Johanna Mäenpää0 个研究点目标入组 796 人开始时间: 2012年3月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 796
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 498
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 298
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 14.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001015-32-FRAGO Research GmbH796
进行中（未招募）
1 期
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 19.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001015-32-DKAGO Research GmbH796
进行中（未招募）
1 期
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001015-32-DEAGO Research GmbH900
招募中
3 期
A randomised phase III trial evaluating the efficacy of more intensive written information in patients having radical radiation therapy.Anxiety levelsPatient satisfaction.Mental Health - AnxietyACTRN12605000705684Perth Radiation Oncology Centre212
进行中（未招募）
不适用
A Phase III randomised, controlled trial of exercise during chemotherapy for patients commencing first line treatment for ovarian cancerCancer - Ovarian and primary peritonealOvarian CancerACTRN12614001311640niversity of Sydney524